Clear All
796 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J1626 Granisetron Hydrochloride Granisol [DSC], Sancuso, Sustol, Kytril 100 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1993 Jan 1, 2009 In Use
C9453 Nivolumab Opdivo 1 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2014 Jul 1, 2015 In Use
Q5115 Rituximab-abbs Truxima 10mg Immunotherapy Monoclonal Antibody CD20 No 2018 Jul 1, 2019 In Use
J3240 Thyrotropin alfa Thyrogen 0.9 mg /1.1 ml vial Hormonal Therapy Thyroid Stimulating Hormone No 1998 Jan 1, 2003 In Use
J9329 Tislelizumab-jsgr Tevimbra 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2024 Sep 11, 2024 In Use
J9185 Fludarabine Fludara 50 mg Chemotherapy Antimetabolite Purine Analog No 1991 Jan 1, 1994 In Use
NA Hydrocortisone Cortef 5mg, 10mg, 20mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Yes 1952 In Use
J2430 Pamidronate disodium Aredia 30mg Ancillary Therapy Bisphosphonate No 1987 In Use
NA Rucaparib Rubraca 200 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
Q5148 Filgrastim-txid (nypozi) Nypozi 1 microgram Ancillary Therapy Immunostimulant Colony-Stimulating Factor No 2024 Mar 26, 2025 In Use
J2919 Methylprednisolone sodium succinate Methylprednisolone sodium succinate 5mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1959 Apr 17, 2024 In Use
Nirogacestat Ogsiveo 50mg, 100mg, 150mg Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Yes 2023 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Megestrol Acetate Megace 20mg, 40mg Hormonal Therapy Progestin Yes 1988 In Use
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Abiraterone acetate Zytiga 250 mg Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Yes 2011 In Use
NA Ruxolitinib Jakafi 25 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
A9534 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic per MC Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jul 1, 2003 In Use
J9207 ixabepilone Ixempra 1mg Chemotherapy Antitumor Antibiotic Epothilones No 2007 Jan 1, 2009 In Use
NA Larotrectinib Vitrakvi 25mg, 100mg 20mg/ml Chemotherapy Tyrosine Kinase Inhibitor TRK Yes 2018 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
NA Pemigatinib Pemazyre 4.5mg, 9mg, 13.5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Yes 2020 In Use
NA Ribociclib and letrozole Kisqali Femara Co-pack 200 mg/ 2.5 mg Chemotherapy, Hormonal Therapy Cyclin dependent kinase inhibitor/ aromatase inhibitor CDK 4/6 Yes 2017 In Use
Q5123 Rituximab-arrx Riabni 10mg Immunotherapy Monoclonal Antibody CD20 No 2021 Jul 23, 2021 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.